The Health Economics of Allergen Immunotherapy

Immunology and Allergy Clinics of North America

Volumn 31, Issue 2, 2011, Pages 325-341

  Hankin, Cheryl S ^a   Cox, Linda ^b   Bronstone, Amy ^a  

^a Moss Beach   (United States)

^b NONE   (United States)

Author keywords

Allergen immunotherapy; Allergic rhinitis; Asthma; Health economics

Indexed keywords

ANTIALLERGIC AGENT; GRASS POLLEN EXTRACT; IMMUNOMODULATING AGENT; PLACEBO; RECOMBINANT ALLERGEN;

ALLERGEN IMMUNOTHERAPY; ALLERGENICITY; ALLERGIC RHINITIS; ALLERGY; ASTHMA; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DECISION TREE; HEALTH CARE COST; HEALTH ECONOMICS; HOUSE DUST ALLERGY; HUMAN; IMMUNOTHERAPY; INTERMETHOD COMPARISON; MEDICARE; NOSE CONGESTION; OUTPATIENT DEPARTMENT; PATIENT CARE; POLLEN ALLERGY; PREVALENCE; PRIORITY JOURNAL; PRURITUS; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; REIMBURSEMENT; REVIEW; RHINORRHEA; SNEEZING; SYMPTOMATOLOGY;

ASTHMA; DESENSITIZATION, IMMUNOLOGIC; HUMANS; RHINITIS, ALLERGIC, PERENNIAL; RHINITIS, ALLERGIC, SEASONAL;

EID: 79955375289     PISSN: 08898561     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.iac.2011.03.007     Document Type: Review

References (47)

1. The American Academy of Allergy, Asthma and Immunology (AAAAI). The Allergy Report 2000, AAAAI, Milwaukee (WI).
2. Wallace D., Dykewicz M., Bernstein D., et al. The diagnosis and management of rhinitis: an updated practice parameter. J Allergy Clin Immunol 2008, 122(2):S1-S84.
3. Chronic conditions - a challenge for the 21st century 1999, National Academy on an Aging Society, Washington, DC.
4. Schoenwetter W.F. Allergic rhinitis: epidemiology and natural history. Allergy Asthma Proc 2000, 21(1):1-6.
5. Meltzer E.O., Blaiss M.S., Derebery M.J., et al. Burden of allergic rhinitis: results from the Pediatric Allergies in America survey. J Allergy Clin Immunol 2009, 124(Suppl 3):S43-S70.
6. Schoenwetter W.F., Dupclay L., Appajosyula S., et al. Economic impact and quality-of-life burden of allergic rhinitis. Curr Med Res Opin 2004, 20(3):305-317.
7. Allergies in America A landmark survey of nasal allergy sufferers. Allergies in America: executive summary 2006, [January 9, 2007]; Available at:, Accessed August 16, 2010. http://www.myallergiesinamerica.com/healthcare/overview.aspx.
8. Meltzer E.O. Quality of life in adults and children with allergic rhinitis. J Allergy Clin Immunol 2001, 108(1):S45-S53.
9. Soni A. Allergic rhinitis: trends in use and expenditures, 2000 and 2005; Statistical brief #204 2008, Agency for Healthcare Research and Quality, Bethesda (MD).
10. Halpern M.T., Schmier J.K., Richner R., et al. Allergic rhinitis: a potential cause of increased asthma medication use, costs, and morbidity. J Asthma 2004, 41(1):117-126.
11. Thomas M., Kocevar V.S., Zhang Q., et al. Asthma-related health care resource use among asthmatic children with and without concomitant allergic rhinitis. Pediatrics 2005, 115(1):129-134.
12. Guilbert T.W., Morgan W.J., Zeiger R.S., et al. Long-term inhaled corticosteroids in preschool children at high risk for asthma. N Engl J Med 2006, 354(19):1985-1997.
13. Leger D., Annesi-Maesano I., Carat F., et al. Allergic rhinitis and its consequences on quality of sleep: an unexplored area. Arch Intern Med 2006, 166(16):1744-1748.
14. Stewart M.G. Identification and management of undiagnosed and undertreated allergic rhinitis in adults and children. Clin Exp Allergy 2008, 38(5):751-760.
15. Cox L., Atwater S. Allergen immunotherapy for allergic rhinitis and asthma. Drug Benefit Trends 2008, 20:1-6.
16. Gold M.R., Siegel J.E., Russell L.B., et al. Cost-Effectiveness in Health and Medicine 1996, Oxford University Press, New York (NY).
17. Cox L., Nelson H., Lockey R., et al. Allergen immunotherapy: a practice parameter third update. J Allergy Clin Immunol 2011, 127(Suppl 1):S1-S55.
18. Sullivan S.D., Weiss K.B. Health economics of asthma and rhinitis. II. Assessing the value of interventions. J Allergy Clin Immunol 2001, 107(2):203-210.
19. Reed S.D., Lee T.A., McCrory D.C. The economic burden of allergic rhinitis: a critical evaluation of the literature. Pharmacoeconomics 2004, 22(6):345-361.
20. Ariano R., Berto P., Tracci D., et al. Pharmacoeconomics of allergen immunotherapy compared with symptomatic drug treatment in patients with allergic rhinitis and asthma. Allergy Asthma Proc 2006, 27(2):159-163.
21. Berto P., Bassi M., Incorvaia C., et al. Cost effectiveness of sublingual immunotherapy in children with allergic rhinitis and asthma. Eur Ann Allergy Clin Immunol 2005, 37(8):303-308.
22. Berto P., Passalacqua G., Crimi N., et al. Economic evaluation of sublingual immunotherapy vs symptomatic treatment in adults with pollen-induced respiratory allergy: the Sublingual Immunotherapy Pollen Allergy Italy (SPAI) study. Ann Allergy Asthma Immunol 2006, 97(5):615-621.
23. Petersen K.D., Gyrd-Hansen D., Dahl R. Health-economic analyses of subcutaneous specific immunotherapy for grass pollen and mite allergy. Allergol Immunopathol (Madr) 2005, 33(6):296-302.
24. Schadlich P.K., Brecht J.G. Economic evaluation of specific immunotherapy versus symptomatic treatment of allergic rhinitis in Germany. Pharmacoeconomics 2000, 17(1):37-52.
25. Bachert C., Vestenbaek U., Christensen J., et al. Cost-effectiveness of grass allergen tablet (GRAZAX(R)) for the prevention of seasonal grass pollen induced rhinoconjunctivitis-a Northern European perspective. Clin Exp Allergy 2007, 37(5):772-779.
26. Keiding H., Jorgensen K.P. A cost-effectiveness analysis of immunotherapy with SQ allergen extract for patients with seasonal allergic rhinoconjunctivitis in selected European countries. Curr Med Res Opin 2007, 23(5):1113-1120.
27. Buchner K., Siepe M. Nutzen der Hyposensibilierung unter wirtschaftlichen Aspekten. Allergo J 1995, 4:156-163. [in German].
28. Omnes L.F., Bousquet J., Scheinmann P., et al. Pharmacoeconomic assessment of specific immunotherapy versus current symptomatic treatment for allergic rhinitis and asthma in France. Eur Ann Allergy Clin Immunol 2007, 39(5):148-156.
29. Hankin C.S., Cox L., Lang D., et al. Allergy immunotherapy among Medicaid-enrolled children with allergic rhinitis: patterns of care, resource use, and costs. J Allergy Clin Immunol 2008, 121(1):227-232.
30. Hankin C.S., Cox L., Lang D., et al. Allergen immunotherapy and health care cost benefits for children with allergic rhinitis: a large-scale, retrospective, matched cohort study. Ann Allergy Asthma Immunol 2010, 104:79-85.
31. Hankin CS, Cox L, Wang Z, et al. Does allergen-specific immunotherapy provide cost benefits for children and adults with allergic rhinitis? Results from large-scale retrospective analyses jointly funded by AAAAI and ACAAI. Oral presentation to be presented at the 2011 Annual Conference of the American Academy of Allergy, Asthma and Immunology. San Francisco (CA), March 18-22, 2011.
32. Le Pen C., Rumeau-Pichen C., Lillin H. L'impact de l'immunothérapie specifique sur le couts directs de la maladie allergique: une etude pragmatique. Rev Franc Allergol Immunol Clin 1997, 37:11-14. [in French].
33. Donahue J.G., Greineder D.K., Connor-Lacke L., et al. Utilization and cost of immunotherapy for allergic asthma and rhinitis. Ann Allergy Asthma Immunol 1999, 82(4):339-347.
34. Bernstein J.A. Pharmacoeconomic considerations for allergen immunotherapy. Allergens and allergen immunotherapy 1999, 445-453. Marcel Dekker, Inc, New York. R.F. Lockey, S.C. Bukantz (Eds.).
35. Available at: Accessed February 15, 2011. http://www.measuringworth.com/index.php.
36. Bureau of Labor Statistics. Consumer Price Index. Available at: Accessed February 15, 2011. http://data.bls.gov/cgi-bin/surveymost%3fcu.
37. Lower T., Henry J., Mandik L., et al. Compliance with allergen immunotherapy. Ann Allergy 1993, 70(6):480-482.
38. Cohn J.R., Pizzi A. Determinants of patient compliance with allergen immunotherapy. J Allergy Clin Immunol 1993, 91(3):734-737.
39. Tinkelman D., Smith F., Cole W.Q., et al. Compliance with an allergen immunotherapy regime. Ann Allergy Asthma Immunol 1995, 74(3):241-246.
40. More D.R., Hagan L.L. Factors affecting compliance with allergen immunotherapy at a military medical center. Ann Allergy Asthma Immunol 2002, 88(4):391-394.
41. Frew A.J., Powell R.J., Corrigan C.J., et al. Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006, 117(2):319-325.
42. National Institute for Clinical Excellence Guide to the methods of technology appraisal 2004, NICE, London.
43. Sheldon T.A. Problems of using modelling in the econonomic evaluation of health care. Health Econ 1996, 5:1-11.
44. Sculpher M.J., Claxton K., Drummond M., et al. Whither trial-based economic evaluation for health care decision making?. Health Econ 2006, 15(7):677-687.
45. Law A.W., Reed S.D., Sundy J.S., et al. Direct costs of allergic rhinitis in the United States: estimates from the 1996 Medical Expenditure Panel Survey. J Allergy Clin Immunol 2003, 111(2):296-300.
46. Cox L., Cohn J.R. Duration of allergen immunotherapy in respiratory allergy: when is enough, enough?. Ann Allergy Asthma Immunol 2007, 98:416-426.
47. Hankin C.S., Lockey R.F. Patient characteristics associated with allergen immunotherapy initiation and adherence. J Allergy Clin Immunol 2011, 127:46-48.